{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:59:27Z","timestamp":1792166367758,"version":"4.4.0"},"reference-count":29,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2016,7,24]]},"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less responsive to conventional chemotherapy than ductal carcinoma. In molecular terms, MBCs usually cluster with triple-negative breast cancers (TNBCs), but have a worse prognosis than TNBCs. Studies investigating MBCs for specific biomarkers of therapy response are rare and limited by the methodological approaches. The aim of the present study was to characterise MBCs on a molecular level and test programmed death-ligand 1 (PD-L1) biomarker expression in MBCs for future therapeutic interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We profiled 297 samples (MBC (n=75), TNBC (n=106), human epidermal growth factor receptor 2 (HER2)-positive breast cancers (n=32) and hormone-positive breast cancers (n=84)) by next-generation sequencing. Immunohistochemistry for PD-L1 and programmed cell death 1 (PD-1) expression was performed using automated procedures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most commonly mutated genes in MBCs included <jats:italic>TP53<\/jats:italic> (56%) and <jats:italic>PIK3CA<\/jats:italic> (23%). Pathogenic mutations in other genes, including <jats:italic>HRAS<\/jats:italic>, <jats:italic>FBXW7<\/jats:italic>, <jats:italic>PTEN<\/jats:italic>, <jats:italic>AKT1<\/jats:italic> and <jats:italic>SMAD4<\/jats:italic>, were rare. PD-L1 expression was detected in a significantly higher proportion of MBCs (46%) than in other subtypes (6% each in hormone-positive and HER2-positive breast cancers, and 9% in TNBC, not otherwise specified, p&lt;0.001). PD-1-positive tumour infiltrating lymphocytes (TILs) varied greatly in MBCs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Comprehensive profiling of a large cohort of this rare subtype of breast carcinoma highlighted the predominance of <jats:italic>TP53<\/jats:italic> mutation and increased PD-L1 expression in carcinoma cells. These results can be exploited in clinical trials using immune checkpoint inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2016-203874","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T22:18:56Z","timestamp":1471385936000},"page":"255-259","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":113,"title":["Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1"],"prefix":"10.1136","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct02447003","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Upasana","family":"Joneja","sequence":"first","affiliation":[{"name":"Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semir","family":"Vranic","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina"},{"name":"School of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Swensen","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Feldman","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjuh","family":"Chen","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kimbrough","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianqing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Reddy","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Gatalica","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,8,16]]},"reference":[{"key":"2025092509152835000_70.3.255.1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198712000-00002"},{"key":"2025092509152835000_70.3.255.2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2162-3619-2-31","article-title":"Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies","volume":"2","author":"Schwartz","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"2025092509152835000_70.3.255.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1686-9"},{"key":"2025092509152835000_70.3.255.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1359-8"},{"key":"2025092509152835000_70.3.255.5","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2014-0200-OA"},{"key":"2025092509152835000_70.3.255.6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2025092509152835000_70.3.255.7","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0654"},{"key":"2025092509152835000_70.3.255.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"2025092509152835000_70.3.255.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025092509152835000_70.3.255.10","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"2025092509152835000_70.3.255.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv192"},{"key":"2025092509152835000_70.3.255.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"2025092509152835000_70.3.255.13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3216"},{"key":"2025092509152835000_70.3.255.14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4494"},{"key":"2025092509152835000_70.3.255.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529"},{"key":"2025092509152835000_70.3.255.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"2025092509152835000_70.3.255.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2025092509152835000_70.3.255.18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689"},{"key":"2025092509152835000_70.3.255.19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4378"},{"key":"2025092509152835000_70.3.255.20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2014","journal-title":"Cancer Res"},{"key":"2025092509152835000_70.3.255.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70208-1"},{"key":"2025092509152835000_70.3.255.22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.124"},{"key":"2025092509152835000_70.3.255.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025092509152835000_70.3.255.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"2025092509152835000_70.3.255.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.09.006"},{"key":"2025092509152835000_70.3.255.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2988-5"},{"key":"2025092509152835000_70.3.255.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.0604"},{"key":"2025092509152835000_70.3.255.28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0116"},{"key":"2025092509152835000_70.3.255.29","doi-asserted-by":"crossref","unstructured":"Gatalica Z , Vanderwalde AM , Rose I , et al . Distribution of PD-L1 expression in diverse cancer types: experience with over 10,000 cases. J Clin Oncol 2016;34(Suppl; abstr 11548).","DOI":"10.1200\/JCO.2016.34.15_suppl.11548"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2016-203874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:15:35Z","timestamp":1758816935000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2016-203874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,16]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,2,16]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1136\/jclinpath-2016-203874"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2016-203874","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,16]]}}}